Approvals
Approvals
- Alert FDA Approves SGLT2 Inhibitor Ertugliflozin for Type 2 Diabetes
- FDA Warns About Amputation Risk With Canagliflozin
- New Continuous Glucose Monitor Software Improves Accuracy
- Alert Trametinib (Mekinist) Now Approved in EU for Melanoma
- Alert FDA Rejects Novo Nordisk's Insulin Degludec
- Alert FDA Approves Higher Dose of Hydromorphone
- First-Time Generic Approvals: AccuNeb, Coreg, Famvir
- Alert Cardiovascular Risks of Haloperidol Highlighted
- New FDA Orphan Drugs: Sodium Phenylbutyrate, MGCD0103, Bendamustine HCl
- Alert FDA Reviewing Proton-Pump Inhibitor Safety
- New FDA Orphan Drugs
- First-Time Generic Approvals: Maxipime, Tessalon 200 mg, Vesanoid
- New FDA Orphan Drugs: Levulan, Vekacia, Hexarelin Analog
- Alert FDA: Antidepressant Labels Must Warn of Suicidality Risk in Young Adults
- New FDA Orphan Drugs: Ganciclovir and Tissue Repair Cells
- New FDA Orphan Drugs: Cethromycin, Maribavir, rhPDGF-BB
- New FDA Orphan Drugs: VariZIG, Pafuramidine Maleate, RG1068
- New FDA Orphan Drugs: MGA031, KBPA101, TLF Oral Solution
- New FDA Orphan Drugs: CellCept, Prochymal, Shiga Toxin Antibodies
- Alert Globus Media Home Medical Tests Illegal, Untested, and May Be Inaccurate